Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives

Yasuhide Kitagawa, Satoru Ueno, Hiroyuki Konaka, Atsushi Mizokami, Shiro Hinotsu, Hideyuki Akaza, Mikio Namiki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Novel anti-androgens and androgen biosynthesis inhibitors have been developed to treat castration-resistant prostate cancer. However, knowledge of androgen deprivation therapy (ADT) has not been developed in the criticism, including information regarding the adverse effects of hormonal therapy. We hypothesize that there are ethnic differences in the efficacy and adverse effects of ADT; therefore, this review summarizes the experience of ADT, mainly in Japan. A risk stratification instrument, the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score, was developed based on the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database. It revealed that clinical outcomes were substantially better for males treated with ADT in Japan compared with those in the United States. Moreover, there were small survival differences in patients with localized and locally advanced cancer who received local therapy and primary ADT in another Japanese cohort study. In terms of adverse effects, including bone loss and cardiovascular risk, ADT appears to be better tolerated in Japanese populations than in Western cohorts. An ongoing randomized controlled trial of a trimodality treatment comprising brachytherapy, external beam radiation therapy, and neoadjuvant with or without adjuvant ADT in patients with localized high-risk prostate cancer will provide novel insights regarding adjuvant ADT. As a future perspective, the optimal selection of the type of primary ADT, including combining androgen blockade and novel hormonal compounds, adjusted according to each patient’s clinicopathological background, may provide better clinical outcomes in patients with advanced prostate cancer.

Original languageEnglish
Pages (from-to)314-326
Number of pages13
JournalCurrent Cancer Drug Targets
Volume15
Issue number4
Publication statusPublished - Jun 1 2015

Fingerprint

Androgens
Prostatic Neoplasms
Japan
Therapeutics
Castration
Brachytherapy
Population
Registries
Cohort Studies
Radiotherapy
Randomized Controlled Trials
Databases
Bone and Bones
Survival

Keywords

  • Androgen deprivation
  • Combined androgen blockade
  • Prostate cancer
  • Risk factor

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Kitagawa, Y., Ueno, S., Konaka, H., Mizokami, A., Hinotsu, S., Akaza, H., & Namiki, M. (2015). Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives. Current Cancer Drug Targets, 15(4), 314-326.

Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives. / Kitagawa, Yasuhide; Ueno, Satoru; Konaka, Hiroyuki; Mizokami, Atsushi; Hinotsu, Shiro; Akaza, Hideyuki; Namiki, Mikio.

In: Current Cancer Drug Targets, Vol. 15, No. 4, 01.06.2015, p. 314-326.

Research output: Contribution to journalArticle

Kitagawa, Y, Ueno, S, Konaka, H, Mizokami, A, Hinotsu, S, Akaza, H & Namiki, M 2015, 'Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives', Current Cancer Drug Targets, vol. 15, no. 4, pp. 314-326.
Kitagawa Y, Ueno S, Konaka H, Mizokami A, Hinotsu S, Akaza H et al. Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives. Current Cancer Drug Targets. 2015 Jun 1;15(4):314-326.
Kitagawa, Yasuhide ; Ueno, Satoru ; Konaka, Hiroyuki ; Mizokami, Atsushi ; Hinotsu, Shiro ; Akaza, Hideyuki ; Namiki, Mikio. / Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives. In: Current Cancer Drug Targets. 2015 ; Vol. 15, No. 4. pp. 314-326.
@article{566a359c8230439182b1564fa84f6f27,
title = "Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives",
abstract = "Novel anti-androgens and androgen biosynthesis inhibitors have been developed to treat castration-resistant prostate cancer. However, knowledge of androgen deprivation therapy (ADT) has not been developed in the criticism, including information regarding the adverse effects of hormonal therapy. We hypothesize that there are ethnic differences in the efficacy and adverse effects of ADT; therefore, this review summarizes the experience of ADT, mainly in Japan. A risk stratification instrument, the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score, was developed based on the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database. It revealed that clinical outcomes were substantially better for males treated with ADT in Japan compared with those in the United States. Moreover, there were small survival differences in patients with localized and locally advanced cancer who received local therapy and primary ADT in another Japanese cohort study. In terms of adverse effects, including bone loss and cardiovascular risk, ADT appears to be better tolerated in Japanese populations than in Western cohorts. An ongoing randomized controlled trial of a trimodality treatment comprising brachytherapy, external beam radiation therapy, and neoadjuvant with or without adjuvant ADT in patients with localized high-risk prostate cancer will provide novel insights regarding adjuvant ADT. As a future perspective, the optimal selection of the type of primary ADT, including combining androgen blockade and novel hormonal compounds, adjusted according to each patient’s clinicopathological background, may provide better clinical outcomes in patients with advanced prostate cancer.",
keywords = "Androgen deprivation, Combined androgen blockade, Prostate cancer, Risk factor",
author = "Yasuhide Kitagawa and Satoru Ueno and Hiroyuki Konaka and Atsushi Mizokami and Shiro Hinotsu and Hideyuki Akaza and Mikio Namiki",
year = "2015",
month = "6",
day = "1",
language = "English",
volume = "15",
pages = "314--326",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Experience with androgen deprivation therapy for prostate cancer in Japan and future perspectives

AU - Kitagawa, Yasuhide

AU - Ueno, Satoru

AU - Konaka, Hiroyuki

AU - Mizokami, Atsushi

AU - Hinotsu, Shiro

AU - Akaza, Hideyuki

AU - Namiki, Mikio

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Novel anti-androgens and androgen biosynthesis inhibitors have been developed to treat castration-resistant prostate cancer. However, knowledge of androgen deprivation therapy (ADT) has not been developed in the criticism, including information regarding the adverse effects of hormonal therapy. We hypothesize that there are ethnic differences in the efficacy and adverse effects of ADT; therefore, this review summarizes the experience of ADT, mainly in Japan. A risk stratification instrument, the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score, was developed based on the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database. It revealed that clinical outcomes were substantially better for males treated with ADT in Japan compared with those in the United States. Moreover, there were small survival differences in patients with localized and locally advanced cancer who received local therapy and primary ADT in another Japanese cohort study. In terms of adverse effects, including bone loss and cardiovascular risk, ADT appears to be better tolerated in Japanese populations than in Western cohorts. An ongoing randomized controlled trial of a trimodality treatment comprising brachytherapy, external beam radiation therapy, and neoadjuvant with or without adjuvant ADT in patients with localized high-risk prostate cancer will provide novel insights regarding adjuvant ADT. As a future perspective, the optimal selection of the type of primary ADT, including combining androgen blockade and novel hormonal compounds, adjusted according to each patient’s clinicopathological background, may provide better clinical outcomes in patients with advanced prostate cancer.

AB - Novel anti-androgens and androgen biosynthesis inhibitors have been developed to treat castration-resistant prostate cancer. However, knowledge of androgen deprivation therapy (ADT) has not been developed in the criticism, including information regarding the adverse effects of hormonal therapy. We hypothesize that there are ethnic differences in the efficacy and adverse effects of ADT; therefore, this review summarizes the experience of ADT, mainly in Japan. A risk stratification instrument, the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score, was developed based on the Japan Study Group of Prostate Cancer registry, which is a large, multicenter, population-based database. It revealed that clinical outcomes were substantially better for males treated with ADT in Japan compared with those in the United States. Moreover, there were small survival differences in patients with localized and locally advanced cancer who received local therapy and primary ADT in another Japanese cohort study. In terms of adverse effects, including bone loss and cardiovascular risk, ADT appears to be better tolerated in Japanese populations than in Western cohorts. An ongoing randomized controlled trial of a trimodality treatment comprising brachytherapy, external beam radiation therapy, and neoadjuvant with or without adjuvant ADT in patients with localized high-risk prostate cancer will provide novel insights regarding adjuvant ADT. As a future perspective, the optimal selection of the type of primary ADT, including combining androgen blockade and novel hormonal compounds, adjusted according to each patient’s clinicopathological background, may provide better clinical outcomes in patients with advanced prostate cancer.

KW - Androgen deprivation

KW - Combined androgen blockade

KW - Prostate cancer

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=84930717874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930717874&partnerID=8YFLogxK

M3 - Article

C2 - 26003144

AN - SCOPUS:84930717874

VL - 15

SP - 314

EP - 326

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 4

ER -